Latest Developments on API Self-Reliance
India has long been recognized as the “pharmacy of the world,” supplying affordable generic medicines to countries across the globe. However, despite its strong formulation manufacturing capabilities, the country has historically relied heavily on imports for Active Pharmaceutical Ingredients (APIs) and key starting materials (KSMs), particularly from China.
In recent years, the Indian government has taken significant steps to reduce this dependence through a series of policy initiatives led by the Department of Pharmaceuticals. Central to this effort is the Production Linked Incentive (PLI) scheme, designed to boost domestic manufacturing of critical APIs, drug intermediates, and key starting materials. These initiatives aim to strengthen supply chain resilience, enhance national health security, and position India as a more integrated pharmaceutical manufacturing hub.
What the Initiative Aims to Achieve
1. Strengthen Domestic API Manufacturing
The Production Linked Incentive (PLI) scheme for bulk drugs provides financial incentives to pharmaceutical manufacturers that invest in domestic production of critical APIs and intermediates. By encouraging companies to establish or expand manufacturing facilities within India, the scheme aims to build sustainable domestic capacity in segments where the country has historically depended on imports.
2. Reduce Import Dependence on Critical Raw Materials
A key objective of the initiative is to reduce India’s reliance on imported APIs and intermediates, particularly those essential for commonly used medicines such as antibiotics, antivirals, and vitamins. Developing domestic capabilities in these areas can help safeguard the country against global supply disruptions and price volatility.
3. Establish Bulk Drug Parks
To further support API manufacturing, the government has launched a scheme to develop dedicated bulk drug parks across selected states. These parks are designed to provide shared infrastructure such as effluent treatment plants, utilities, and testing facilities, reducing operational costs for manufacturers while improving efficiency and environmental compliance.
4. Encourage Investment and Technology Upgradation
Through financial incentives, infrastructure development, and policy support, the government aims to attract both domestic and international investment into India’s API manufacturing sector. The focus also includes encouraging technology adoption and process innovation to ensure that Indian facilities remain globally competitive.
Why API Self-Reliance Matters Now
The COVID-19 pandemic highlighted vulnerabilities in global pharmaceutical supply chains. Temporary disruptions in the supply of APIs and intermediates exposed the risks associated with overdependence on a limited number of international suppliers.
For a country like India, which produces a large share of the world’s generic medicines, securing the upstream supply of raw materials is critical. Strengthening domestic API production can enhance supply chain stability, protect the pharmaceutical industry from external shocks, and support uninterrupted access to essential medicines.
At the same time, increasing local production can help India capture more value across the pharmaceutical manufacturing chain, rather than focusing primarily on finished formulations.
Potential Impact on India’s Pharmaceutical Landscape
Revival of Domestic Bulk Drug Industry
Government incentives and infrastructure support are expected to revive India’s bulk drug manufacturing sector, which had gradually declined over the past two decades due to cost advantages in other markets.
Improved Supply Chain Resilience
By developing domestic capabilities in critical APIs and intermediates, India can build a more resilient pharmaceutical supply chain that is less vulnerable to global disruptions.
Expansion of Manufacturing Ecosystem
The development of bulk drug parks and increased investment in API production may create a broader manufacturing ecosystem, supporting job creation, regional industrial development, and technological advancement.
Enhanced Global Competitiveness
Strengthening upstream manufacturing capabilities will enable Indian pharmaceutical companies to integrate more of the value chain domestically, improving competitiveness in global markets and reinforcing India’s position as a key supplier of affordable medicines.
Conclusion
India’s push toward API self-reliance represents a strategic shift in pharmaceutical policy. Through initiatives such as the Production Linked Incentive scheme and the development of bulk drug parks, the government is working to rebuild domestic manufacturing capacity for critical pharmaceutical ingredients.
If successfully implemented, these efforts could significantly reduce import dependence, strengthen supply chain security, and enhance India’s role as a comprehensive global pharmaceutical manufacturing hub capable of producing both active ingredients and finished medicines.
No Comment! Be the first one.